6990.HK
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
HKSEHKDEQUITY
DELAYED
Last price
523.00
▼ 15.00 (2.79%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
540.00
Prev close
538.00
Day high
543.00
Day low
516.50
Volume
543.74K
Market cap
—
P/E (TTM)
—
52W range
339.60 – 581.00
Day trading desk
Gap from prior close
+0.37%
Prior close 538.00
VWAP
523.11
-0.02% from price
Relative volume
—
—
Session range
5.13%
516.50 – 543.00
Position in range
25%
Near session low
ATR (14D)
27.15
5.19% of price
Prior day high
545.00
PDH
Prior day low
527.50
PDL
Bid / ask spread
—
Quote not published
Session volume
1.24M
Shares traded
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+0.10%
+1.5%
1M
+1.75%
-2.0%
3M
+10.29%
+7.2%
6M
+24.94%
+13.9%
YTD
+32.94%
+20.7%
1Y
+25.00%
+5.0%
3Y
+515.29%
+441.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on 6990.HK open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.06B | $1.93B | $1.54B | $803.93M | +6.5% |
| Operating revenue | $2.06B | $1.93B | $1.54B | $803.93M | +6.5% |
| Cost of revenue | $579.14M | $659.39M | $781.31M | $276.83M | -12.2% |
| Gross profit | $1.48B | $1.27B | $759.18M | $527.11M | +16.1% |
| Research & development | $1.32B | $1.21B | $1.03B | $845.98M | +9.4% |
| Selling, general & admin | $284.72M | $129.23M | $66.17M | $22.87M | +120.3% |
| Total operating expense | $1.94B | $1.49B | $1.21B | $921.03M | +31.0% |
| Operating income | -$466.19M | -$211.40M | -$452.61M | -$393.93M | -120.5% |
| Net interest income | $57.38M | $30.38M | -$39.12M | -$147.40M | +88.9% |
| Pre-tax income | -$355.78M | -$142.54M | -$467.69M | -$567.36M | -149.6% |
| Tax provision | $26.19M | $124.22M | $106.44M | $48.73M | -78.9% |
| Net income | -$381.97M | -$266.77M | -$574.13M | -$616.10M | -43.2% |
| Net income to common | -$381.97M | -$266.77M | -$522.21M | -$548.10M | -43.2% |
| Basic EPS | -1.66 | -1.20 | -2.84 | -2.54 | -38.3% |
| Diluted EPS | -1.66 | -1.20 | -2.84 | -2.54 | -38.3% |
| EBIT | -$349.62M | -$138.75M | -$383.38M | -$418.55M | -152.0% |
| EBITDA | -$249.23M | -$47.36M | -$308.31M | -$351.19M | -426.2% |
| Basic shares | 230.54M | 221.65M | 183.63M | 215.83M | +4.0% |
| Diluted shares | 230.54M | 221.65M | 183.63M | 215.83M | +4.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.33B | $1.34B | $1.57B | $119.22M | — | +148.0% |
| Cash & short-term investments | $4.56B | $3.08B | $2.53B | $119.22M | — | +48.2% |
| Accounts receivable | $94.47M | $57.84M | $0 | $0 | — | +63.3% |
| Inventory | $240.94M | $110.51M | $63.03M | $52.64M | — | +118.0% |
| Total current assets | $5.15B | $3.49B | $2.81B | $332.32M | — | +47.4% |
| Property, plant & equipment | $722.50M | $721.24M | $654.99M | $609.21M | — | +0.2% |
| Goodwill & intangibles | $37.09M | $39.45M | $39.08M | $41.80M | — | -6.0% |
| Total assets | $5.99B | $4.27B | $3.51B | $993.14M | — | +40.3% |
| Total current liabilities | $1.00B | $809.84M | $1.11B | $4.17B | — | +24.0% |
| Current debt | — | — | $0 | $2.89B | $2.39B | — |
| Total debt | $88.44M | $126.75M | $59.92M | $3.01B | — | -30.2% |
| Total liabilities | $1.12B | $959.34M | $1.18B | $4.22B | — | +16.9% |
| Retained earnings | -$4.71B | -$4.32B | -$4.06B | -$3.48B | — | -8.8% |
| Shareholder equity | $4.87B | $3.31B | $2.33B | -$3.23B | — | +47.1% |
| Working capital | $4.14B | $2.68B | $1.70B | -$3.84B | — | +54.5% |
| Net tangible assets | $4.83B | $3.27B | $2.29B | -$3.27B | — | +47.7% |
| Shares issued | 233.19M | 227.27M | 219.20M | 215.83M | — | +2.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$355.78M | -$142.54M | -$467.69M | -$567.36M | -149.6% |
| Depreciation & amortisation | $100.40M | $91.39M | $75.08M | $67.36M | +9.9% |
| Stock-based compensation | $170.69M | $148.28M | $123.35M | $19.81M | +15.1% |
| Change in working capital | -$91.95M | -$481.24M | $275.52M | $34.52M | +80.9% |
| Operating cash flow | -$180.30M | -$429.77M | $59.56M | -$270.85M | +58.0% |
| Capital expenditure | -$126.25M | -$81.12M | -$82.25M | -$38.99M | -55.6% |
| Investing cash flow | $411.01M | -$822.00M | -$1.03B | -$32.15M | +150.0% |
| Financing cash flow | $1.73B | $1.04B | $2.38B | $313.45M | +66.6% |
| Free cash flow | -$306.55M | -$510.89M | -$22.69M | -$309.84M | +40.0% |
| End cash position | $3.24B | $1.34B | $1.53B | $92.96M | +142.7% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $3.33B | $3.12B | $1.34B | +6.9% |
| Cash & short-term investments | $4.56B | $4.53B | $3.08B | +0.7% |
| Accounts receivable | $94.47M | $202.04M | $57.84M | -53.2% |
| Inventory | $240.94M | $200.20M | $110.51M | +20.4% |
| Total current assets | $5.15B | $5.19B | $3.49B | -0.8% |
| Property, plant & equipment | $722.50M | $741.35M | $721.24M | -2.5% |
| Goodwill & intangibles | $37.09M | $1.70M | $39.45M | +2,078.0% |
| Total assets | $5.99B | $5.95B | $4.27B | +0.6% |
| Total current liabilities | $1.00B | $790.35M | $809.84M | +27.1% |
| Total debt | $88.44M | $131.08M | $126.75M | -32.5% |
| Total liabilities | $1.12B | $938.60M | $959.34M | +19.5% |
| Retained earnings | -$4.71B | -$4.47B | -$4.32B | -5.3% |
| Shareholder equity | $4.87B | $5.01B | $3.31B | -2.9% |
| Working capital | $4.14B | $4.40B | $2.68B | -5.9% |
| Net tangible assets | $4.83B | $5.01B | $3.27B | -3.6% |
| Shares issued | 233.19M | 233.19M | 227.27M | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
528.55
-1.05% from price
SMA 20
514.14
+1.72% from price
SMA 50
487.62
+7.26% from price
SMA 100
472.25
+10.75% from price
SMA 200
448.20
+16.69% from price
EMA 12
524.85
-0.35% from price
EMA 26
513.27
+1.90% from price
EMA 50
495.90
+5.47% from price
RSI (14)
53.7
Neutral
MACD (12,26,9)
11.57
Hist -0.54
ATR (14)
27.15
5.19% of price
Realised vol 30D
45.7%
Annualised
Bollinger upper
555.85
20, 2σ
Bollinger lower
472.43
20, 2σ
50 / 200 cross
Golden
487.62 vs 448.20
Trend bias
Above 200
+16.69%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.05
Less volatile than market
Correlation to SPY
0.01
Largely independent
Realised vol 30D
45.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-39.7%
Peak to trough
Max drawdown 5Y
-39.7%
Peak to trough
ATR 14
27.15
5.19% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Educators Head Into the New School Year with Measured Optimism--and a Discerning Eye on AI's Role in the Classroom
PR Newswire · 2m ago
Cathie Wood Dumps $27.2 Million of Palantir Stock After 43% Rally
GuruFocus.com · 2m ago
United Therapeutics Says FDA Accepted Application for Pulmonary Arterial Hypertension Treatment
MT Newswires · 4m ago
Nvidia's Next AI Bet Could Be Perplexity
GuruFocus.com · 8m ago
Stocks Down Pre-Bell as Investors Await Key Inflation Data, Warsh Speech, Nvidia Earnings
MT Newswires · 9m ago
Rocket One Inc. to Attend IDGA's Counter UAS Summit August 25 - 26, 2026
PR Newswire · 9m ago
3 Non-Tech Thriving Nasdaq Stocks Enabling Its Northward Move in 2026
Zacks · 9m ago
Net Asset Value(s)
Business Wire · 9m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.